

Q-linea wins public tender for rapid AST

Q-linea AB (publ) (OMX: QLINEA) today announces that the company has received an awarding of a public tender for rapid AST instruments and consumables issued by Fondazione PTV – Tor Vergata in Rome, Italy.

The tender has a validity for five years and a total value of EUR 600,000 and the company expects the formalization of the awarding in 35 days. The equipment will be used at the Policlinico Tor Vergata University of Rome.

Franco Pellegrini, General Manager for Italy/Southern Europe commented, "We are extremely pleased with the outcome of this project. Several companies have been involved in the bidding and ASTar has been selected as preferred system based on the highest score between technical and pricing criteria. This is the first evidence of the proven competitiveness of our solution and an important milestone for future tenders and projects to come".

"It feels really good to share the news that we won the first tender we participated in. We started earlier in Italy compared to our distributor markets and therefore expect to be able to share more positive news in other geographies going forward. Sales cycles are indeed long, but at the same time we see that the tender in Italy is stimulating more tenders, which indicates that the market is starting to see the value of rapid AST. ASTar has performed strongly in the evaluations with customers during the year and it is nice to see that it is now starting to bear fruit. I also hope that this gives our shareholders the first proof that they have invested in a company with a competitive product," said Jonas Jarvius, CEO and President at Q-linea.

About ASTar Instruments and ASTar BC G-Kit

ASTar Instrument and ASTar BC G-Kit already deliver the broadest answer regarding the combination of the number of antibiotics and the number of double dilution steps of each antibiotic, in a single analysis for gram-negative bacteria. The test enables the analysis of gram-negative bacteria, including difficult-to-grow so-called fastidious bacteria, which satisfies the need for rapid and comprehensive results to support optimal treatment decisions.

ASTar Instrument and ASTar BC G-Kit are CE-marked but not FDA 510(k)-cleared and not available for sale in the United States.

For more information, please contact:

Jonas Jarvius, CEO, Q-linea AB

Jonas.Jarvius@qlinea.com

+46 (0) 70-323 77 60

Christer Samuelsson, CFO /IR, Q-linea AB

Christer.Samuelsson@qlinea.com

+46 (0) 70-600 15 20

About Q-linea

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar[®] is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

Attachments

[Q-linea wins public tender for rapid AST](#)